08225.HK
China Health Group Inc.
HKSE · Healthcare · Medical - Diagnostics & Research · CN
HKD 0.08
−1.23%Year over year
Reported trailing growth
- Revenue
- +55.6%
- EBITDA
- +118.7%
- EBIT
- +133.8%
- EPS
- -54.7%
- Free cash flow
- -23.9%
- Operating cash flow
- -33.7%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +28.6%
- EBITDA
- +1.3%
- EBIT
- +2.6%
- Net income
- -0.4%
- EPS
- +0.0%
- Free cash flow
- +5.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026